Uncovering new approaches to a common inherited heart disorder
New Yale research provides a mechanism to identify abnormalities linked with hypertrophic cardiomyopathy, the most common hereditary cardiac condition. (Source: Yale Science and Health News)
Source: Yale Science and Health News - July 29, 2022 Category: Universities & Medical Training Source Type: news

May 13 2022 This Week in Cardiology May 13 2022 This Week in Cardiology
Obstructive hypertrophic cardiomyopathy and mavacamten, SGLT2 inhibitors, the triple whammy, espresso, and clinician burnout are the topics John Mandrola, MD, covers in today ’s podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 13, 2022 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

FDA Approves Camzyos (mavacamten) for the Treatment of Symptomatic NYHA Class II-III Obstructive Hypertrophic Cardiomyopathy
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of adults with symptomatic New... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 30, 2022 Category: Drugs & Pharmacology Source Type: news

FDA OKs heart drug at center of $13 billion deal for Peninsula company
A heart drug at the center of Bristol-Myers Squibb Co.'s $13 billion acquisition of a Peninsula company 18 months ago was approved Thursday by federal regulators. Mavacamten, which will be branded as Camzyos and sold for $89,500 a year after the Food and Drug Administration's approval, is designed to treat adults with symptomatic obstructive hypertrophic cardiomyopathy, or HCM, a genetic heart condition. HCM makes the heart wall thicken so the heart pumps blood less efficiently. The condition,… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 29, 2022 Category: Health Management Authors: Ron Leuty Source Type: news

Cardiac Myosin Inhibitor Gets FDA's Blessing for Obstructive HCM
(MedPage Today) -- The FDA approved mavacamten (Camzyos) for the treatment of obstructive hypertrophic cardiomyopathy (HCM) in people with New York Heart Association class II-III symptoms -- but on the condition it would only be available through... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 29, 2022 Category: Cardiology Source Type: news

ACC: Mavacamten Cuts Need for Surgery in Hypertrophic Cardiomyopathy
MONDAY, April 11, 2022 -- For patients with obstructive hypertrophic cardiomyopathy (HCM), mavacamten improves symptoms and reduces the need for septal reduction therapy (SRT), according to a study presented at the annual meeting of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 11, 2022 Category: Pharmaceuticals Source Type: news

Mavacamten Controlled Hypertrophic Cardiomyopathy for > 1 Year Mavacamten Controlled Hypertrophic Cardiomyopathy for > 1 Year
Open-label mavacamten for a median of 62 weeks in patients with symptomatic obstructive hypertrophic cardiomyopathy showed ongoing safety and efficacy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 4, 2022 Category: Cardiology Tags: Cardiology News Source Type: news

VALOR-HCM: Novel Drug May Delay, Avert Invasive Therapy in OHCM VALOR-HCM: Novel Drug May Delay, Avert Invasive Therapy in OHCM
A medical alternative to highly invasive septal reduction therapy for patients with obstructive hypertrophic cardiomyopathy and symptoms despite standard meds? Perhaps, a randomized trial suggests.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 2, 2022 Category: Cardiology Tags: Cardiology News Source Type: news

Add-On Mavacamten Cuts Need for Septal Reduction in Obstructive HCM
(MedPage Today) -- WASHINGTON – Treatment with investigational mavacamten allowed patients with advanced obstructive hypertrophic cardiomyopathy (oHCM) to avoid septal reduction therapies (SRT), a researcher reported. In the VALOR-HCM study... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - April 2, 2022 Category: Surgery Source Type: news

Obstructive HCM: Will Septal Reduction Zapping Hold Up?
(MedPage Today) -- Operators continued to make progress on an investigational septal reduction procedure for drug-refractory obstructive hypertrophic cardiomyopathy (HCM) at the Chinese center that pioneered the technique. Among 200 patients... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - March 30, 2022 Category: Surgery Source Type: news

New Tool Detects Difficult-to-Diagnose Cardiac Conditions New Tool Detects Difficult-to-Diagnose Cardiac Conditions
A new algorithm has been developed that can reliably detect two cardiovascular conditions -- hypertrophic cardiomyopathy and cardiac amyloidosis -- that are often difficult to diagnose.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 17, 2022 Category: Cardiology Tags: Cardiology News Source Type: news

Sex and race disparities found in management of patients with hypertrophic cardiomyopathy in the hospital
ROCHESTER, Minn. — In recent decades, implantable cardioverter-defibrillator (ICD) use in the management of patients with hypertrophic cardiomyopathy (HCM) has increased. However, a new Mayo Clinic study finds that ICDs are not used as often for female patients and patients of color. Data from the National Inpatie nt Sample, an all-payer administrative database of inpatient hospitalizations, showed disparities regarding which patients commonly receive this therapy in the hospital. The data also revealed regional variations in the… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 7, 2021 Category: Databases & Libraries Source Type: news

Mayo Clinic Q & amp;A podcast: Justin's journey and silver linings
At the age of 15, Justin Vigile was diagnosed with hypertrophic cardiomyopathy, a genetic condition that causes the muscles of the heart to thicken, making it difficult for the heart to pump blood. Vigile had a cardiac defibrillator placed, but over time, his heart began to fail. When looking for answers and help, Vigile and his family turned to Mayo Clinic. Thanks to science, research and an innovative procedure performed by the man who developed… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 24, 2021 Category: Databases & Libraries Source Type: news

Sudden Cardiac Death in Hypertrophic Cardiomyopathy Sudden Cardiac Death in Hypertrophic Cardiomyopathy
Differences in sudden cardiac death risk stratification algorithms in US and European practice guidelines for hypertrophic cardiomyopathy are a source of discord and confusion.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 12, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

AF Ablation in Patients With Hypertrophic Cardiomyopathy AF Ablation in Patients With Hypertrophic Cardiomyopathy
A new study finds modest success rates for catheter ablation for AF in patients with hypertrophic cardiomyopathy, but this commentary points out several caveats to consider.Europace (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 12, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news